Ra Pharmaceuticals,Inc. (NASDAQ:RARX) Files An 8-K Regulation FD Disclosure
Item7.01.Regulation FD Disclosure.
Ra Pharmaceuticals,Inc. (the Company) is furnishing a corporate
presentation, attached as Exhibit99.1 to this Current Report on
Form8-K, which the Company intends to use from time to time in
meetings with investors and others beginning on April4, 2017. The
corporate presentation will also be available on the Companys
website at
The information in this Item 7.01 and Exhibit99.1 attached hereto
shall not be deemed filed for purposes of Section18 of the
Securities and Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor shall they be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, except as expressly set forth
by specific reference in such filing.
Item9.01.Financial Statements and
Exhibits.
(d)Exhibits
|
Exhibit No. |
|
Description |
|
99.1 |
Ra Pharmaceuticals,Inc., corporate presentation. |
About Ra Pharmaceuticals, Inc. (NASDAQ:RARX)
Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) Recent Trading Information
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) closed its last trading session down -0.34 at 20.34 with 66,926 shares trading hands.
